Addex Therapeutics Presents Positive Results From GABAB PAM Cough Program
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Addex Therapeutics (ADXN) announced that it will present positive results from its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) chronic cough program at the Thirteenth London International Cough Symposium on July 19.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-88296471-df4a2527f7b64b33b1e9f5652d5583a7.jpg "<div>How NYC's Yellow Cab Works and Makes Money</div>")
:max_bytes(150000):strip_icc():format(jpeg)/FlyFirstClassforCheap-d3852e14d3984fddb9a46fcb17fc93c2.jpg "How to Fly First Class for Cheap")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-506997606-3aeda39d7c734e459725400f855c816d.jpg "Is Shopping at Big-Box Stores Worth It? Factors to Consider")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1169041231-5052d200552d467baab33417938984a3.jpg "10 Low-Risk Income Sources for a Safer Retirement")